Key result
SCN5A non-missense variants linked to more lifetime lethal arrhythmias than missense variants in Brugada syndrome.
Why the study?
SCN5A loss-of-function variants cause Brugada syndrome and associate with poor prognosis, but which specific variant types affect carrier prognosis remained unelucidated.
Do SCN5A non-missense variants increase the risk of lethal arrhythmia events compared to missense variants in patients with Brugada syndrome?
Cohort (n=76)
Do SCN5A non-missense variants increase the risk of lethal arrhythmia events compared to missense variants in patients with Brugada syndrome?
SCN5A non-missense variants are associated with a higher lifetime probability of lethal arrhythmia events than missense variants in Brugada syndrome patients.
Answers are grounded in this paper and cite their sources.
May support SCN5A variant-specific risk stratification in Brugada syndrome; leaves open prospective validation before practice change.
AIMS: The variant in SCN5A with the loss of function (LOF) effect in the cardiac Na+ channel (Nav1.5) is the definitive cause for Brugada syndrome (BrS), and the functional analysis data revealed that LOF variants are associated with poor prognosis. However, which variant types (e.g. missense or non-missense) affect the prognoses of those variant carriers remain unelucidated. METHODS AND RESULTS: We defined SCN5A LOF variants as all non-missense and missense variants that produce peak INa < 65% of wild-type previously confirmed by patch-clamp studies. The study population consisted of 76 Japanese BrS patients (74% patients were male and the median age [IQR] at diagnosis was 28 [14-45] years) with LOF type of SCN5A variants: 40 with missense and 36 with non-missense variants. Non-missense variant carriers presented significantly more severe cardiac conduction disorder compared to the missense variant carriers. During follow-up periods of 9.0 [5.0-14.0] years, compared to missense variants, non-missense variants were significant risk factors of lifetime lethal arrhythmia events (LAEs) (P = 0.023). When focusing only on the missense variants that produce no peak INa, these missense variant carriers exhibited the same clinical outcomes as those with non-missense (log-rank P = 0.325). After diagnosis, however, both variant types were comparable in risk of LAEs (P = 0.155). CONCLUSION: We identified, for the first time, that SCN5A non-missense variants were associated with higher probability of LAE than missense variants in BrS patients though it did not change significantly after diagnosis.
No takes yet. Share an insight, caveat, or question.
Aizawa et al. (2025) conducted a cohort in Brugada syndrome (n=76). SCN5A non-missense variants vs. SCN5A missense variants was evaluated on Lifetime lethal arrhythmia events (LAEs) (p=0.023). SCN5A non-missense variants were associated with a higher risk of lifetime lethal arrhythmia events compared to missense variants in Brugada syndrome patients.
Synapse has enriched 10 related papers. Consider them for comparative context: